DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
The Non-Small Cell Lung Cancer market report provides current treatment practices, emerging drugs, Non-Small Cell Lung Cancer market share of the individual therapies, current and forecasted Non-Small Cell Lung Cancer market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Non-Small Cell Lung Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Study Period: 2017-2030
Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases.
There are mainly two types of lung cancer Small cell lung cancer (SCLC) and Non-small cell lung cancer (NSCLC).
NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers (IASLC, n.d.). However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. If untreated, SCLC can be fatal in a few weeks, in contrast to most cases of NSCLC.
NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas.
In the United States, according to the data published by the Institute for Clinical and Economic Review (ICER) and the National Institutes of Health (NIH) out of the total lung cancer cases approximately 85% of lung cancers are NSCLC. Among those cases, squamous cell carcinoma comprised 30% cases, adenocarcinoma comprised of 40% cases, and large-cell carcinoma comprised 15% cases. Also, all other country based registries have mentioned almost same percentage for NSCLC and its major subtypes.
NSCLC can be located in the mid-chest, but it is often also found in other parts of the lung too. Even though NSCLCs are associated with cigarette smoking, adenocarcinomas may also be found in patients who have never smoked. Also, itis relatively insensitive to chemotherapy and radiation therapy in comparison with SCLC.
NSCLC arises from the epithelial cells of the lung of the central bronchi to terminal alveoli. The histological type of NSCLC correlates with the site of origin, reflecting the variation in respiratory tract epithelium of the bronchi to alveoli. While squamous cell carcinoma starts near a central bronchus usually, Adenocarcinoma and bronchioloalveolar carcinoma typically originate in peripheral lung tissue.
The symptoms of NSCLC and SCLC can be similar, which may include a persistent cough, chest pain, shortness of breath, wheezing, loss of appetite, weight loss, and unusual tiredness.
Although tobacco smoking is the major risk factor for either type of lung cancer, a substantial number of patients diagnosed with lung cancer have no prior history of smoking. Besides, exposure to passive smoking, asbestos, and radon may also increase the risk of developing lung cancer.
Patients of NSCLC with the resectable disease may be cured by surgery or surgery followed by chemotherapy. Local control can be achieved by radiation therapy in a large number of patients with unresectable disease. On the other hand, patients with the locally advanced unresectable disease may achieve long-term survival with radiation therapy combined with chemotherapy and the patients with advanced metastatic disease may achieve improved survival and palliation of symptoms with chemotherapy, targeted agents, and other supportive measures
Diagnosis
The diagnosis and staging of NSCLC are often done at the same time. The tests and procedures used in the diagnosis of NSCLC are Physical exam and history, Laboratory tests, Chest X-ray, CT scan, Sputum cytology, Thoracentesis, Fine-needle aspiration (FNA) biopsy of the Lung, Bronchoscopy, Thoracoscopy, Mediastinoscopy, Anterior Mediastinotomy, Lymph node biopsy, Molecular test, Immunohistochemistry, among others.
Some of the tests that are used to diagnose NSCLC also determine the stage of the disease such as MRI (magnetic resonance imaging), CT scan, PET scan (positron emission tomography scan), bone scan, pulmonary function test (PFT), and bone marrow aspiration and biopsy. The staging system of NSCLC is divided into various stages such as Occult (hidden) cancer, Stage 0, Stage IA1, IA2, IA3, IB, IIA, IIB, IIIA, IIIB, IIIC, IVA, and IVB.
Treatment
There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include: Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.
Chemotherapy is used to stop the growth of cancer cells, either by killing the cells or by stopping their division. Targeted therapy is a type of treatment that uses drugs or other substances to attack specific cancer cells. These therapies usually cause less harm to normal cells than chemotherapy or radiation therapy. Monoclonal antibodies and tyrosine kinase inhibitors are the two main types of targeted therapy being used to treat advanced, metastatic, or recurrent NSCLC. Immunotherapy is a type of treatment that uses the patients’ immune system to fight cancer. Radiation therapy uses high-energy x-rays or other types of radiations to kill cancer cells or keep them from developing.
The therapies that are approved for the treatment of NSCLC are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab), among others.
The Non-Small Cell Lung Cancer epidemiology division provides the insights about historical and current Non-Small Cell Lung Cancer patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology segmented as [Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies] scenario of NSCLC in the 7MM covering the United States, EU5 countries (Germany, France, Italy , Spain, and United Kingdom), and Japan from 2017 to 2030.
Key Findings
Country Wise- Non-Small Cell Lung Cancer Epidemiology
The epidemiology segment also provides the Non-Small Cell Lung Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Drug chapter segment of the Non-Small Cell Lung Cancer report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Non-Small Cell Lung Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Non-Small Cell Lung Cancer Approved Drug
1. Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)
2. Imfinzi (Durvalumab): AstraZeneca
3. Opdivo (Nivolumab): Bristol-Myers Squibb
4. Tecentriq (Atezolizumab): Hoffmann-La Roche
5. Keytruda (Pembrolizumab): Merck
6. Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib): Novartis
7. Tagrisso (Osimertinib): AstraZeneca
8. Lorbrena/Lorviqua (Lorlatinib): Pfizer
9. Vizimpro (Dacomitinib): Pfizer
10. Alunbrig (Brigatinib): Takeda Pharmaceuticals
11. Alecensa (Alectinib): Hoffmann-La Roche
12. Vitrakvi (Larotrectinib): Bayer Healthcare
13. Portrazza (Necitumumab): Eli Lilly and Company
Note: Detailed Current therapies assessment will be provided in the full report of NSCLC
Non-Small Cell Lung Cancer Emerging Drugs
1. Nazartinib/EGF816: Novartis Pharmaceuticals
2. Capmatinib/INC280: Novartis Pharmaceuticals
3. Telisotuzumab Vedotin: AbbVie
4. JNJ-61186372/JNJ-6372: Janssen Pharmaceuticals
5. Ensartinib/X-396: Xcovery
6. Selpercatinib (LY3527723/LOXO-292): Eli Lilly and Company
7. SAR408701: Sanofi
8. Braftovi/encorafinib + Mektovi/binimetinib: Pfizer
9. PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics
10. TAK-788: Takeda Pharmaceuticals
11. Canakinumab/(ACZ885): Novartis
12. BAVENCIO (Avelumab): Merck/Pfizer
13. Veliparib: AbbVie
14. Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene
15. M7824: Merck/GlaxoSmithKline
16. AMG 510: Amgen
17. INCMGA00012 (MGA012): Incyte Corporation
18. Romiplostim: Amgen
19. TEPMETKO (tepotinib): Merck
Note: Detailed emerging therapies assessment will be provided in the final report.
There are several treatment options available to treat this condition in the seven major markets. Typically, chemotherapy, targeted treatments, and immunotherapy—alone or in combination—are used to treat lung cancer. Besides, pharmacological treatment choices, surgery, and radiation are also frequently opted. When the patient is in the initial stages, the tumor is usually resectable. Most stage I and stage II NSCLC are treated with surgery to remove the tumor.
To recommend a treatment option to a patient of NSCLC, several key factors are taken into consideration, such as age of the patient, previous medical history, health status, and smoking history. Along with these, another essential factor to consider is the stage of cancer at the time of diagnosis. Staging is usually carried out twice: after clinical and radiological examinations; and after surgery, in the case of the surgically resected tumor. Furthermore, biological testing of the tumor is also crucial to understand the presence of specific mutations.
The main choice of treatment for cancer, before the discovery of targeted therapies was chemotherapy. Chemotherapy works by disrupting the way that cancer cells grow and divide. However, these drugs can also affect normal cells. Chemotherapy can be given before or after surgery for NSCLC. Some people have chemotherapy at the same time as radiotherapy this is called chemoradiotherapy. Chemotherapy may be given to try to cure cancer or to prolong life and control symptoms (palliative care).
One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments. Unlike chemotherapy drugs, which cannot tell the difference between normal cells and cancer cells, targeted therapies are designed to attack cancer cells specifically by attaching to or blocking targets that appear on the surfaces of those cells. People who have advanced lung cancer with certain molecular biomarkers may receive treatment with a targeted drug alone or in combination with chemotherapy.
As several institutes and pharmacological companies indulged themselves in a more in-depth understanding of this disease, therapies for advanced NSCLC have developed significantly with a new awareness of histologic subtypes. It is an important factor in guiding treatment and the development of targeted agents for molecular subgroups harboring critical mutations that spur on cancer growth.
Key Findings
According to DelveInsight, Non-Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017–2030. The total therapeutic market of Non-Small Cell Lung Cancer in seven major markets was found to be USD 9,730 million in 2017 which is expected to increase during the study period (2017–2030).
The United States Market Outlook
In 2017, the total market size of Non-Small Cell Lung Cancer for five mutation therapies i.e. PD-L1, EGFR, ALK, BRAF, C-MET was estimated to be USD 5,562.6 million in the United States which is expected to increase in the study period (2017–2030).
EU-5 Countries: Market Outlook
Germany
In 2017, the total market size of Non-Small Cell Lung Cancer for five mutation therapies i.e. PD-L1, EGFR, ALK, BRAF, C-MET was estimated to be USD 772.8 million in Germany which is expected to increase in the study period (2017–2030).
France
In 2017, the total market size of Non-Small Cell Lung Cancer for five mutation therapies i.e. PD-L1, EGFR, ALK, BRAF, C-MET was estimated to be USD 577.4 million in France which is expected to increase in the study period (2017–2030).
Italy
In 2017, the total market size of Non-Small Cell Lung Cancer for five mutation therapies i.e. PD-L1, EGFR, ALK, BRAF, C-MET was estimated to be USD 506 million in Italy which is expected to increase in the study period (2017–2030).
Spain
In 2017, the total market size of Non-Small Cell Lung Cancer for five mutation therapies i.e. PD-L1, EGFR, ALK, BRAF, C-MET was estimated to be USD 360 million in Spain which is expected to increase in the study period (2017–2030).
The United Kingdom
In 2017, the total market size of Non-Small Cell Lung Cancer for five mutation therapies i.e. PD-L1, EGFR, ALK, BRAF, C-MET was estimated to be USD 590.5 million in the United Kingdom which is expected to increase in the study period (2017–2030).
Japan Market Outlook
In 2017, the total market size of Non-Small Cell Lung Cancer for five mutation therapies i.e. PD-L1, EGFR, ALK, BRAF, C-MET was estimated to be USD 1,360.4 million in Japan which is expected to increase in the study period (2017–2030).
According to the current scenario of NSCLC and our analysis majority of patients fall into two mutations i.e. PD-L1 and EGFR with major percentage share in the market.
Other therapies like JNJ-6372 and TAK-788 which are mainly targeting EGFR exon 20 insertion mutations are expected to generate good revenue in the coming years.
The drugs which are in pipeline include:
1. Nazartinib/EGF816: Novartis Pharmaceuticals
2. Capmatinib/INC280: Novartis Pharmaceuticals
3. Telisotuzumab Vedotin: AbbVie
4. JNJ-61186372/JNJ-6372: Janssen Pharmaceuticals
5. Ensartinib/X-396: Xcovery
6. Selpercatinib (LY3527723/LOXO-292): Eli Lilly and Company
7. SAR408701: Sanofi
8. Braftovi/encorafinib + Mektovi/binimetinib: Pfizer
9. PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics
10. TAK-788: Takeda Pharmaceuticals
11. Canakinumab/(ACZ885): Novartis
12. BAVENCIO (Avelumab): Merck/Pfizer
13. Veliparib: AbbVie
14. Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene
15. M7824: Merck/GlaxoSmithKline
16. AMG 510: Amgen
17. INCMGA00012 (MGA012): Incyte Corporation
18. Romiplostim: Amgen
19. TEPMETKO (tepotinib): Merck
Note: Detailed emerging therapies assessment will be provided in the final report.
The current scenario of therapeutics for NSCLC is mainly based on the use of targeted therapies and immunotherapy’s. Especially the current paradigm is mainly associated with treatment specific to mutations that occur in NSCLC. NSCLC is characterized by the availability of a high number of branded therapies such as Keytruda, Opdivo, Tecentriq, Tagrisso, and others. Due to the high costs, some of the therapies are not able to show their cost-effectiveness and are unable to get a recommendation by assessment agencies. So, the access and reimbursement scenario of drugs for NSCLC is not easy as cost-effectiveness is a major barrier for therapies in NSCLC.
The recommendation of some drugs by NICE which are approved for NSCLC are Opdivo (Nivolumab), Tagrisso (osimertinib), Alunbrig (brigatinib), Keytruda (pembrolizumab), Nintedanib in combination with docetaxel, Durvalumab, Atezolizumab with carboplatin and nab-paclitaxel, among others.
To keep up with current market trends, we take KOLs and SME's opinion working in Non-Small Cell Lung Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Non-Small Cell Lung Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Non-Small Cell Lung Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
1. Key Insights
2. Executive Summary of NSCLC
3. SWOT Analysis of NSCLC
4. NSCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of NSCLC in 2017: By Country
4.2. Total Market Share (%) Distribution of NSCLC in 2030: By Country
4.3. Total Market Share (%) Distribution of NSCLC in 2017: By Mutations/ biomarkers
4.4. Total Market Share (%) Distribution of NSCLC in 2030: By Mutations/ biomarkers
4.5. NSCLC Revenue Summary by Mutations/ biomarkers
5. Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Cellular Classification of NSCLC
5.1.2. Signs and Symptoms of NSCLC
5.1.3. Risk Factors of Lung Cancer
5.1.4. Causes of NSCLC
5.1.5. Disease Biology: NSCLC
6. Diagnosis of NSCLC
6.1. Diagnostic Algorithm for NSCLC
6.2. Stages of NSCLC
6.3. Staging System
7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Incident cases of NSCLC patients in the 7MM
7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Incident cases of NSCLC patients in the United States
7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
7.4.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United States
8. EU-5 Epidemiology
8.1. Germany
8.1.1. Total Incident cases of NSCLC patients in Germany
8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
8.1.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Germany
8.2. France
8.2.1. Total Incident cases of NSCLC patients in France
8.2.2. Total Incident cases of NSCLC patients by Histology in France
8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
8.2.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in France
8.3. Italy
8.3.1. Total Incident cases of NSCLC patients in Italy
8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
8.3.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Italy
8.4. Spain
8.4.1. Total Incident cases of NSCLC patients in Spain
8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
8.4.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Spain
8.5. The United Kingdom
8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
8.5.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United Kingdom
9. Japan Epidemiology
9.1. Japan
9.1.1. Total Incident cases of NSCLC patients in Japan
9.1.2. Total Incident cases of NSCLC patients by Histology in Japan
9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
9.1.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Japan
10. Current Treatment Practices: NSCLC
10.1. Advanced/Metastatic NSCLC Treatment Algorithm
10.2. Chemotherapy
10.3. Targeted Therapy
10.4. Immunotherapy
10.5. Surgery
10.6. Radiation Therapy
10.7. Stage-wise Treatment Options of NSCLC
11. Guideline of NSCLC
11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020
11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018
11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018
12. Unmet Needs of NSCLC
13. Key Endpoints in NSCLC Clinical Trials
14. Marketed Therapies
14.1. Key Cross
14.2. Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)
14.2.1. Product Description
14.2.2. Regulatory Milestones
14.2.3. Other Developmental Activities
14.2.4. Pivotal Clinical Trials
14.2.5. Ongoing Current Pipeline Activity
14.3. Imfinzi (Durvalumab): AstraZeneca
14.3.1. Product Description
14.3.2. Regulatory Milestones
14.3.3. Other Developmental Activities
14.3.4. Pivotal Clinical Trials
14.3.5. Ongoing Current Pipeline Activity
14.3.6. Safety and Efficacy of Ongoing Clinical Trials
14.4. Opdivo (Nivolumab): Bristol-Myers Squibb
14.4.1. Product Description
14.4.2. Regulatory Milestones
14.4.3. Other Developmental Activities
14.4.4. Pivotal Clinical Trials
14.4.5. Ongoing Current Pipeline Activity
14.5. Tecentriq (Atezolizumab): Genentech/Hoffmann-La Roche
14.5.1. Product Description
14.5.2. Regulatory Milestones
14.5.3. Other Developmental Activities
14.5.4. Pivotal Clinical Trials
14.5.5. Ongoing Current Pipeline Activity
14.6. Keytruda (Pembrolizumab): Merck
14.6.1. Product Description
14.6.2. Regulatory Milestones
14.6.3. Other Developmental Activities
14.6.4. Pivotal Clinical Trials
14.6.5. Ongoing Current Pipeline Activity
14.7. Tafinlar(Dabrafenib)in Combination with Mekinist(Trametinib): Novartis
14.7.1. Product Description
14.7.2. Regulatory Milestones
14.7.3. Other Developmental Activities
14.7.4. Pivotal Clinical Trials
14.8. Tagrisso(Osimertinib): AstraZeneca
14.8.1. Product Description
14.8.2. Regulatory Milestones
14.8.3. Other Developmental Activities
14.8.4. Pivotal Clinical Trials
14.8.5. Ongoing Current Pipeline Activity
14.9. Lorbrena/Lorviqua (Lorlatinib): Pfizer
14.9.1. Product Description
14.9.2. Regulatory Milestones
14.9.3. Other Developmental Activities
14.9.4. Pivotal Clinical Trials
14.9.5. Ongoing Current Pipeline Activity
14.10. Vizimpro(Dacomitinib): Pfizer
14.10.1. Product Description
14.10.2. Regulatory Milestones
14.10.3. Other Developmental Activities
14.10.4. Pivotal Clinical Trials
14.10.5. Ongoing Current Pipeline Activity
14.11. Alunbrig (Brigatinib): Takeda Pharmaceuticals
14.11.1. Product Description
14.11.2. Regulatory Milestones
14.11.3. Pivotal Clinical Trials
14.11.4. Ongoing Current Pipeline Activity
14.11.5. Safety and Efficacy of Ongoing Clinical Trials
14.12. Alecensa (Alectinib): Hoffmann-La Roche
14.12.1. Product Description
14.12.2. Regulatory Milestones
14.12.3. Other Developmental Activities
14.12.4. Pivotal Clinical Trials
14.12.5. Ongoing Current Pipeline Activity
14.13. Vitrakvi (Larotrectinib): Bayer Healthcare
14.13.1. Product Description
14.13.2. Regulatory Milestones
14.13.3. Other Developmental Activities
14.13.4. Pivotal Clinical Trials
14.13.5. Safety and Efficacy
14.14. Portrazza (Necitumumab): Eli Lilly
14.14.1. Product Description
14.14.2. Regulatory Milestones
14.14.3. Other Developmental Activities
14.14.4. Pivotal Clinical Trials
14.14.5. Ongoing Current Pipeline Activity
15. Emerging Therapies
15.1. Nazartinib (EGF816): Novartis Pharmaceuticals
15.1.1. Product Description
15.1.2. Clinical Development
15.1.3. Safety and Efficacy
15.2. Capmatinib (INC280): Novartis Pharmaceuticals
15.2.1. Product Description
15.2.2. Other Development Activities
15.2.3. Clinical Development
15.2.4. Safety and Efficacy
15.3. Tepmetko (tepotinib): Merck KGaA
15.3.1. Product Description
15.3.2. Other Development Activities
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.4. Merestinib: Eli Lilly and Company
15.4.1. Product Description
15.4.2. Clinical Development
15.4.3. Telisotuzumab Vedotin: AbbVie
15.4.4. Product Description
15.4.5. Clinical Development
15.4.6. Safety and Efficacy
15.5. JNJ-61186372 (JNJ-6372): Janssen Research & Development
15.5.1. Product Description
15.5.2. Other Development Activity
15.5.3. Clinical Development
15.5.4. Safety and Efficacy
15.6. Lazertinib: Yuhan Corporation/ Janssen Research & Development
15.6.1. Product Description
15.6.2. Clinical Development
15.6.3. Safety and Efficacy
15.7. Vemurafenib Plus Cobimetinib: Hoffmann-La Roche
15.7.1. Product Description
15.7.2. Clinical Development
15.7.3. Safety and Efficacy
15.8. X-396 (Ensartinib): Xcovery
15.8.1. Product Description
15.8.2. Clinical Development
15.8.3. Safety and Efficacy
15.9. Plinabulin: BeyondSpring Pharmaceuticals
15.9.1. Product Description
15.9.2. Clinical Development
15.9.3. Safety and Efficacy
15.10. (OSE2101): OSE Immunotherapeutics
15.10.1. Description
15.10.2. Development
15.10.3 Safety and Efficacy
15.11. Selpercatinib (LY3527723/ LOXO-292): Eli Lilly and Company
15.11.1. Product Description
15.11.2. Clinical Development
15.11.3. Safety and Efficacy
15.12. SAR408701: Sanofi
15.12.1. Product Description
15.12.2. Clinical Development
15.13. Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer
15.13.1. Product Description
15.13.2. Clinical Development
15.14. PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics
15.14.1. Product Description
15.14.2. Clinical Development
15.15. Pralsetinib (BLU-667): Blueprint Medicines Corporation
15.15.1. Product Description
15.15.2. Clinical Development
15.15.3. Safety and Efficacy
15.16.TAK-788: Takeda
15.16.1. Product Description
15.16.2. Clinical Development
15.16.3. Safety and Efficacy
15.17. Canakinumab (ACZ885): Novartis Pharmaceuticals
15.17.1. Product Description
15.17.2. Clinical Development
15.18. Avelumab (Bavencio): Merck KGaA and Pfizer
15.18.1. Product Description
15.18.2. Clinical Development
15.18.3. Safety and Efficacy
15.19. Veliparib (ABT-888): AbbVie
15.19.1.Product Description
15.19.2.Clinical Development
15.19.3. Safety and Efficacy
15.20. Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene
15.20.1. Product Description
15.20.2. Other Developmental Activities
15.20.3. Clinical Development
15.20.4. Safety and Efficacy
15.21. Tesevatinib: Kadmon Corporation
15.21.1. Product Description
15.21.2. Clinical Development
15.21.3. Safety and Efficacy
15.22. Romiplostim: Amgen
15.22.1. Product Description
15.22.2. Clinical Development
15.23. Cabozantinib: Exelixis/Ipsen/Takeda
15.23.1. Product Description
15.23.2. Other Development Activities
15.23.3. Clinical Development
15.23.4. Safety and Efficacy
15.24. Sym015: Symphogen
15.24.1. Product Description
15.24.2. Clinical Development
15.24.3. Safety and Efficacy
15.25. AMG 510: Amgen
15.25.1. Product Description
15.25.2. Clinical Development
15.25.3. Safety and Efficacy
15.26. INCMGA00012 (MGA012): Incyte Corporation/ Zai Lab Limited
15.26.1. Product Description
15.26.2. Clinical Development
15.27. Libtayo (Cemiplimab): Regeneron Pharmaceuticals
15.27.1. Product Description
15.27.2. Clinical Development
15.27.3. Safety and Efficacy
15.28. Bavituximab: Peregrine Pharmaceuticals/ Avid Bioservices, Inc
15.28.1. Product Description
15.28.2. Clinical Development
15.28.3. Safety and Efficacy
15.29. M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA
15.29.1. Product Description
15.29.2. Clinical Development
15.29.3. Safety and Efficacy
16. Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
16.1. Key Findings
16.2. Market Outlook: 7MM
17. PD-L1—Market Size
17.1. Total Market Size of PD-L1 NSCLC in the 7MM
17.2. Market Size of PD-L1 NSCLC by Therapeutic Class in the 7MM
17.3. United States Market Size
17.3.1. Total Market size of PD-L1 NSCLC in the United States
17.4. EU-5 Market Size
17.4.1. Germany Market Size
17.4.2. France Market Size
17.4.3. Italy Market Size
17.4.4. Spain Market Size
17.4.5. United Kingdom Market Size
17.5. Japan Market Size
17.5.1. Total Market size of PD-L1 NSCLC in Japan
18. BRAF Mutation—Market Size
18.1. Total Market Size of BRAF NSCLC in the 7MM
18.2. Market Size of BRAF-NSCLC by Therapeutic Class in the 7MM
18.3. United States Market Size
18.3.1. Total Market size of BRAF NSCLC in the United States
18.4. EU-5 Market Size
18.4.1. Germany Market Size
18.4.2. France Market Size
18.4.3. Italy Market Size
18.4.4. Spain Market Size
18.4.5. United Kingdom Market Size
18.5. Japan Market Size
18.5.1. Total Market size of BRAF NSCLC in Japan
19. c-MET Mutation—Market Size
19.1. Total Market Size of c-MET NSCLC in the 7MM
19.2. Market Size of c-MET NSCLC by Therapeutic Class in the 7MM
19.3. United States Market Size
19.3.1. Total Market size of c-MET NSCLC in the United States
19.4. EU-5 Market Size
19.4.1. Germany Market Size
19.4.2. France Market Size
19.4.3. Italy Market Size
19.4.4. Spain Market Size
19.4.5. United Kingdom Market Size
19.5. Japan Market Size
19.5.1. Total Market size of c-MET NSCLC in Japan
20. EGFR Mutation—Market Size
20.1. Total Market Size of EGFR-positive NSCLC in the 7MM
20.2. Market Size of EGFR-positive NSCLC by Therapeutic Class in the 7MM
20.3. United States Market Size
20.3.1. Total Market size of EGFR NSCLC in the United States
20.4. EU-5 Market Size
20.4.1. Germany Market Size
20.4.2. France Market Size
20.4.3. Italy Market Size
20.4.4. Spain Market Size
20.4.5. United Kingdom Market Size
20.5. Japan Market Size
20.5.1. Total Market size of NSCLC in Japan
21. ALK-Mutation—Market Size
21.1. Total Market Size of ALK NSCLC in the 7MM
21.2. Market Size of ALK NSCLC by Therapeutic Class in the 7MM
21.3. United States Market Size
21.3.1. Total Market size of ALK NSCLC in the United States
21.4. EU-5 Market Size
21.4.1. Germany Market Size
21.4.2. France Market Size
21.4.3. Italy Market Size
21.4.4. Spain Market Size
21.4.5. United Kingdom Market Size
21.5. Japan Market Size
21.5.1. Total Market size of NSCLC in Japan
22. Market Access and Reimbursement of NSCLC Therapies
23. Market Drivers of NSCLC
24. Market Barriers of NSCLC
25. Appendix
25.1. Bibliography
25.2. Report Methodology
26. DelveInsight Capabilities
27. Disclaimer
28. About DelveInsight
Table 1: Summary of Non-small-cell Lung Cancer (NSCLC) Market, Epidemiology, and Key Events (2017–2030)
Table 2: TNM Staging of NSCLC
Table 3: Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Table 4: Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Table 5: Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Table 6: Total Incident cases of NSCLC patients in the United States (2017–2030)
Table 7: Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Table 8: Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Table 9: Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United States (2017–2030)
Table 10: Total Incident cases of NSCLC patients in Germany (2017–2030)
Table 11: Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Table 12: Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Table 13: Total NSCLC cases of patients by Genetic mutation/Biomarkers in Germany (2017–2030)
Table 14: Total Incident cases of NSCLC patients in France (2017–2030)
Table 15: Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Table 16: Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Table 17: Total NSCLC cases of patients by Genetic mutation/Biomarkers in France (2017–2030)
Table 18: Total Incident cases of NSCLC patients in Italy (2017–2030)
Table 19: Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Table 20: Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Table 21: Total NSCLC cases of patients by Genetic mutation/Biomarkers in Italy (2017–2030)
Table 22: Total Incident cases of NSCLC patients in Spain (2017–2030)
Table 23: Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Table 24: Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Table 25: Total NSCLC cases of patients by Genetic mutation/Biomarkers in Spain (2017–2030)
Table 26: Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Table 27: Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Table 28: Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Table 29: Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United Kingdom (2017–2030)
Table 30: Total Incident cases of NSCLC patients in Japan (2017–2030)
Table 31: Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Table 32: Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Table 33: Total NSCLC cases of patients by Genetic mutation/Biomarkers in Japan (2017–2030
Table 34: Standard Treatment Options of NSCLC (Stage-wise)
Table 35: Summary of Recommendations (SEOM Clinical Guideline)
Table 36: Strength of Evidence
Table 37: Strength of Evidence
Table 38: Marketed Drugs Key Cross
Table 39:Rozlytrek (Entrectinib), Clinical Trial Description, 2020
Table 40:Imfinzi (Durvalumab), Clinical Trial Description, 2020
Table 41:Opdivo (Nivolumab), Clinical Trial Description, 2020
Table 42:Tecentriq (Atezolizumab), Clinical Trial Description, 2020
Table 43:Keytruda (Pembrolizumab), Clinical Trial Description, 2020
Table 44:Tagrisso (Osimertinib), Clinical Trial Description, 2020
Table 45:Lorbrena (Lorlatinib), Clinical Trial Description, 2020
Table 46:Vizimpro (Dacomitinib), Clinical Trial Description, 2020Table 47:Alunbrig (Brigatinib), Clinical Trial Description, 2020
Table 48:Alecensa (Alectinib), Clinical Trial Description, 2020
Table 49:Portrazza (Necitumumab), Clinical Trial Description, 2020
Table 50: Nazartinib (EGF816), Clinical Trial Description, 2020
Table 51: Capmatinib (INC280), Clinical Trial Description, 2020
Table 52: Tepotinib, Clinical Trial Description, 2020
Table 53: Merestinib, Clinical Trial Description, 2020
Table 54: Telisotuzumab Vedotin (ABBV-399), Clinical Trial Description, 2020
Table 55: JNJ-61186372 (JNJ-6372), Clinical Trial Description, 2020
Table 56: Lazertinib (YH25448), Clinical Trial Description, 2020
Table 57: Vemurafenib Plus Cobimetinib, Clinical Trial Description, 2020
Table 58: X-396 (Ensartinib), Clinical Trial Description, 2020
Table 59: Plinabulin, Clinical Trial Description, 2020
Table 60: Tedopi (OSE2101), Clinical Trial Description, 2020
Table 61: Selpercatinib (LY3527723/ LOXO-292), Clinical Trial Description, 2020
Table 62: SAR408701, Clinical Trial Description, 2020
Table 63: Braftovi (encorafinib) + Mektovi (binimetinib), Clinical Trial Description, 2020
Table 64: Enfortumab vedotin, Clinical Trial Description, 2020
Table 65: Pralsetinib, Clinical Trial Description, 2020
Table 66: TAK-788, Clinical Trial Description, 2020
Table 67: Canakinumab (ACZ885), Clinical Trial Description, 2020
Table 68: Avelumab, Clinical Trial Description, 2020
Table 69: Veliparib (ABT-888), Clinical Trial Description, 2020
Table 70: Sitravatinib (MGCD516), Clinical Trial Description, 2020
Table 71: Tesevatinib, Clinical Trial Description, 2020
Table 72: Romiplostim, Clinical Trial Description, 2020
Table 73: Cabozantinib (XL184), Clinical Trial Description, 2020
Table 74: Sym015, Clinical Trial Description, 2020
Table 75: AMG 510, Clinical Trial Description, 2020
Table 76: Libtayo (cemiplimab) Clinical Trial Description, 2020
Table 77: AMG 510, Clinical Trial Description, 2020
Table 78: M7824 (Bintrafusp alfa), Clinical Trial Description, 2020
Table 79: 7MM Market Size of PD-L1 NSCLC, in USD Million (2017–2030)
Table 80: 7MM Market Size of PD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 81: 7MM Market Size ofPD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 82: United States Market Size ofPD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 83: United States Market Size ofPD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 84: Germany Market Size of PD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 85: Germany Market Size of PD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 86: France Market Size ofPD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 87: France Market Size ofPD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 88: Italy Market Size ofPD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 89: Italy Market Size ofPD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 90: Spain Market Size ofPD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 91: Spain Market Size of PD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 92: United Kingdom Market Size of PD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 93: United Kingdom Market Size of PD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 94: Japan Market Size of PD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 95: Japan Market Size ofPD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 96: 7MM Market Size of BRAF NSCLC in USD Million (2017–2030)
Table 97: 7MM Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 98: 7MM Market Size of BRAF NSCLC by therapies, in USD Million (2017–2030)
Table 99: United States Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 100: United States Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 101: Germany Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 102: Germany Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 103: France Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 104: France Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 105: Italy Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 106: Italy Market Size ofBRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 107: Spain Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 108: Spain Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 109: United Kingdom Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 110: United Kingdom Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 111: Japan Market Size of BRAF NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 112: Japan Market Size of BRAF NSCLC by Therapies, in USD Million (2017–2030)
Table 113: 7MM Market Size of c-MET NSCLC, in USD Million (2017–2030)
Table 114: 7MM Market Size of c-MET NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 115: 7MM Market Size of c-MET NSCLC by therapies, in USD Million (2017–2030)
Table 116: United States Market Size of c-MET NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 117: United States Market Size of c-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 118: Germany Market Size of c-MET NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 119: Germany Market Size of c-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 120: France Market Size ofc-MET NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 121: France Market Size of c-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 122: Italy Market Size of c-MET NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 123: Italy Market Size of c-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 124: Spain Market Size of c-MET NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 125: Spain Market Size of c-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 126: United Kingdom Market Size of c-MET NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 127: United Kingdom Market Size of c-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 128: Japan Market Size of c-MET NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 129: Japan Market Size ofc-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 130: 7MM Market Size of EGFR-positive NSCLC, in USD Million (2017–2030)
Table 131: 7MM Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 132: 7MM Market Size of EGFR-positive NSCLC by therapies in USD Million (2017–2030)
Table 133: United States Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 134: United States Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 135: Germany Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 136: Germany Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 137: France Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 138: France Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 139: Italy Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 140: Italy Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 141: Spain Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 142: Spain Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 143: United Kingdom Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 144: United Kingdom Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 145: Japan Market Size of EGFR-positive NSCLC By Line of Therapy in USD Million (2017–2030)
Table 146: Japan Market Size of EGFR-positive NSCLC by Therapies in USD Million (2017–2030)
Table 147: 7MM Market Size of ALK NSCLC, in USD Million (2017–2030)
Table 148: 7MM Market Size of ALK NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 149: 7MM Market Size of ALK NSCLC by therapies, in USD Million (2017–2030)
Table 150: United States Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 151: United States Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 152: Germany Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 153: Germany Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 154: France Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 155: France Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 156: Italy Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 157: Italy Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 158: Spain Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 159: Spain Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 160: United Kingdom Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 161: United Kingdom Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 162: Japan Market Size of ALK NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 163: Japan Market Size of ALK NSCLC by Therapies, in USD Million (2017–2030)
Table 164: National Institute for Health and Care Excellence (NICE) Decisions for NSCLC Therapies
Table 165: IQWiG Decisions for NSCLC Therapies
Table 166: Haute Autorité de santé (HAS) Decisions for NSCLC Therapies
Figure 1: NSCLC SWOT Analysis
Figure 2: Major Types of NSCLC
Figure 3: Sign and Symptoms of NSCLC
Figure 4: Risks Factors of NSCLC
Figure 5: Alterations in Targetable Oncogenic Pathways in LUAD and LUSC
Figure 6: Schematic Illustration of the NSCLC Staging
Figure 7: Stage IA Lung Cancer
Figure 8: Stage IB Lung Cancer
Figure 9: Stage IIA Lung Cancer
Figure 10: Stage IIB Lung Cancer
Figure 11: Stage IIIA Lung Cancer
Figure 12: Stage IIIB Lung Cancer
Figure 13: Stage IVA Lung Cancer
Figure 14: Global Heat Map of Lung Cancer
Figure 15: Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Figure 16: Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Figure 17: Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Figure 18: Total Incident cases of NSCLC patients in the United States (2017–2030)
Figure 19: Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Figure 20: Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Figure 21: Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United States (2017–2030)
Figure 22: Total Incident cases of NSCLC patients in Germany (2017–2030)
Figure 23: Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Figure 24: Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Figure 25: Total NSCLC cases of patients by Genetic mutation/Biomarkers in Germany (2017–2030)
Figure 26: Total Incident cases of NSCLC patients in France (2017–2030)
Figure 27: Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Figure 28: Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Figure 29: Total NSCLC cases of patients by Genetic mutation/Biomarkers in France (2017–2030)
Figure 30: Total Incident cases of NSCLC patients in Italy (2017–2030)
Figure 31: Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Figure 32: Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Figure 33: Total NSCLC cases of patients by Genetic mutation/Biomarkers in Italy (2017–2030)
Figure 34: Total Incident cases of NSCLC patients in Spain (2017–2030)
Figure 35: Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Figure 36: Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Figure 37: Total NSCLC cases of patients by Genetic mutation/Biomarkers in Spain (2017–2030)
Figure 38: Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Figure 39: Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Figure 40: Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Figure 41: Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United Kingdom (2017–2030)
Figure 42: Total Incident cases of NSCLC patients in Japan (2017–2030)
Figure 43: Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Figure 44: Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Figure 45: Total NSCLC cases of patients by Genetic mutation/Biomarkers in Japan (2017–2030)
Figure 46: Advanced/Metastatic NSCLC Treatment Algorithm
Figure 47: Timeline Illustrating the Development of Targeted Therapies and Immunotherapies for the Treatment of NSCLC Over two decades
Figure 48: Immune Checkpoint Inhibitor
Figure 49: Unmet Needs
Figure 50: Market Size ofPD-L1 NSCLC in the 7MM Countries, in USD Million (2017–2030)
Figure 51: Market Size of PD-L1 NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 52: Market Size ofPD-L1 NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 53: Market Size ofPD-L1 NSCLC in the United States by Therapies, in USD Million (2017–2030)
Figure 54: Market Size ofPD-L1 NSCLC in Germany by Therapies, in USD Millions (2017–2030)
Figure 55: Market Size ofPD-L1 NSCLC in France by Therapies, in USD Millions (2017–2030)
Figure 56: Market Size ofPD-L1 NSCLC in Italy by Therapies, in USD Millions (2017–2030)
Figure 57: Market Size ofPD-L1 NSCLC in Spain by Therapies, in USD Millions (2017–2030)
Figure 58: Market Size of PD-L1 NSCLC in the United Kingdom by Therapies, in USD Millions (2017–2030)
Figure 59: Market Size of PD-L1 NSCLC in Japan, in USD Millions (2017–2030)
Figure 60: Market Size of BRAF NSCLC in the 7MM Countries in USD Million (2017–2030)
Figure 61: Market Size of BRAF NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 62: Market Size of BRAF NSCLC by therapies in the 7MM, in USD Million (2017–2030)
Figure 63: Market Size of BRAF NSCLC in the United States by Therapies, in USD Millions (2017–2030)
Figure 64: Market Size of BRAF NSCLC in Germany by Therapies, in USD Millions (2017–2030)
Figure 65: Market Size of BRAF NSCLC in France by Therapies, in USD Millions (2017–2030)
Figure 66: Market Size of BRAF NSCLC in Italy by Therapies, in USD Millions (2017–2030)
Figure 67: Market Size of BRAF NSCLC in Spain by Therapies, in USD Millions (2017–2030)
Figure 68: Market Size of BRAF NSCLC in the United Kingdom by Therapies, in USD Millions (2017–2030)
Figure 69: Market Size of BRAF NSCLC by Therapies in Japan, in USD Millions (2017–2030)
Figure 70: Market Size of c-MET NSCLC in the 7MM Countries, in USD Million (2017–2030)
Figure 71: Market Size of c-MET NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 72: Market Size of c-MET NSCLC by therapies by in the 7MM, in USD Million (2017–2030)
Figure 73: Market Size of c-MET NSCLC in the United States by Therapies, in USD Millions (2017–2030)
Figure 74: Market Size of c-MET NSCLC in France, in USD Millions (2017–2030)
Figure 75: Market Size of c-MET NSCLC by therapies in Italy, in USD Millions (2017–2030)
Figure 76: Market Size of c-MET NSCLC by therapies in Spain, in USD Millions (2017–2030)
Figure 77: Market Size of c-MET NSCLC by Therapies in the United Kingdom, in USD Millions (2017–2030)
Figure 78: Market Size of c-MET NSCLC by therapies in Japan, in USD Millions (2017–2030)
Figure 79: Market Size of EGFR-positive NSCLC in the 7MM, in USD Million (2017–2030)
Figure 80: Market Size of EGFR-positive NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 81: Market Size of EGFR-positive NSCLC by therapies in the 7MM, in USD Million (2017–2030)
Figure 82: Market Size of EGFR-positive NSCLC in the US, USD Millions (2017–2030)
Figure 83: Market Size of EGFR-positive NSCLC in Germany, USD Millions (2017–2030)
Figure 84: Market Size of NSCLC in France, USD Millions (2017–2030)
Figure 85: Market Size of EGFR-positive NSCLC in Italy, USD Millions (2017–2030)
Figure 86: Market Size of EGFR-positive NSCLC in Spain, USD Millions (2017–2030)
Figure 87: Market Size of EGFR-positive NSCLC in the United Kingdom USD Millions (2017–2030)
Figure 88: Market Size of NSCLC in Japan, USD Millions (2017–2030)
Figure 89: Market Size of ALK NSCLC in the 7MM, in USD Million (2017–2030)
Figure 90: Market Size of ALK NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 91: Market Size of ALK NSCLC by therapies by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 92: Market Size of ALK NSCLC in the United States by Therapies, in USD Millions (2017–2030)
Figure 93: Market Size of ALK NSCLC in Germany by Therapies, in USD Millions (2017–2030)
Figure 94: Market Size of ALK NSCLC in France by Therapies, in USD Millions (2017–2030)
Figure 95: Market Size of ALK NSCLC in Italy by Therapies, in USD Millions (2017–2030)
Figure 96: Market Size of ALK NSCLC in Spain by Therapies, in USD Millions (2017–2030)
Figure 97: Market Size of ALK NSCLC in the United Kingdom by Therapies, in USD Millions (2017–2030)
Figure 98: Market Size of ALK NSCLC in Japan by Therapies, in USD Millions (2017–2030)
Figure 99: Market Drivers
Figure 100: Market Barriers
1. Nazartinib/EGF816: Novartis Pharmaceuticals
2. Capmatinib/INC280: Novartis Pharmaceuticals
3. Telisotuzumab Vedotin: AbbVie
4. JNJ-61186372/JNJ-6372: Janssen Pharmaceuticals
5. Ensartinib/X-396: Xcovery
6. Selpercatinib (LY3527723/LOXO-292): Eli Lilly and Company
7. SAR408701: Sanofi
8. Braftovi/encorafinib + Mektovi/binimetinib: Pfizer
9. PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics
10. TAK-788: Takeda Pharmaceuticals
11. Canakinumab/(ACZ885): Novartis
12. BAVENCIO (Avelumab): Merck/Pfizer
13. Veliparib: AbbVie
14. Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene
15. M7824: Merck/GlaxoSmithKline
16. AMG 510: Amgen
17. INCMGA00012 (MGA012): Incyte Corporation
18. Romiplostim: Amgen
19. TEPMETKO (tepotinib): Merck
